Latest Hepatitis D Stories
- Results Presented at European Association for the Study of the Liver (EASL) Meeting in Vienna, Austria PALO ALTO, Calif., April 27, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals,
PALO ALTO, Calif., April 20, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Incorporated today announced that the U.S.
-NIH Principal Investigator to Present Abstract and Poster at Conference on Retroviruses and Opportunistic Infections (CROI) PALO ALTO, Calif., Feb.
RnRMarketResearch.com adds "Hepatitis D - Pipeline Review, H2 2014" to its store. This report provides an overview of the Hepatitis D's therapeutic pipeline. DALLAS, Dec.
PALO ALTO, Calif., Dec.
PALO ALTO, Calif., Dec, 22, 2014 /PRNewswire/ -- Eiger BioPharmaceuticals Incorporated announced the positive results of a Phase 2a study of lonafarnib in patients with chronic hepatitis delta
PALO ALTO, Calif., Dec. 22, 2014 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that lonafarnib has been granted Orphan Designation by the U.S.
MOSCOW, October 21, 2014 /PRNewswire/ -- Hepatera Ltd and its development partner MYR GmbH announced today the results of clinical trials investigating Myrcludex B in patients
Hepatitis C is a contagious liver disease which results from infection with the Hepatitis C virus (HCV), which is spread primarily through contact with the blood of an infected person.
In its May 2014 survey, polyDNA found that 36% of respondents wanted to know what complications can arise from a hepatitis B infection.
- Emitting flashes of light; glittering.